Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage

Acta Ophthalmologica, 04/20/2012

Both initial treatment regimen lead to improved functional results after 1 year. However, patients, not suffering from adverse events, who underwent initial treatment with recombinant tissue plasminogen activator (rtPA) and gas showed better results. To maintain visual acuity, controlling neovascular age–related macular degeneration by anti–Vascular Endothelial Growth Factor treatment regime after initial treatment with rtPA+gas is important for all cases.

Print Article Summary